Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Share-based Compensation: 2024-2025

Historic Share-based Compensation for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $11.0 million.

  • Kura Oncology's Share-based Compensation rose 31.73% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year change of. This contributed to the annual value of $33.9 million for FY2024, which is 20.71% up from last year.
  • Per Kura Oncology's latest filing, its Share-based Compensation stood at $11.0 million for Q3 2025, which was up 57.79% from $6.9 million recorded in Q2 2025.
  • Kura Oncology's Share-based Compensation's 5-year high stood at $11.0 million during Q3 2025, with a 5-year trough of $6.9 million in Q2 2025.